Core Viewpoint - The recent delisting of SPACs associated with Chinese companies has halted their plans for U.S. listings, highlighting the risks of the SPAC model and the unique value of the OTC market [1] Group 1: SPAC Delisting and Its Implications - Nasdaq delisted 13 securities on January 13, including three SPACs (Four Leaf, DT Cloud, AlphaTime) linked to Chinese companies, transferring them to the OTC market [1] - The delisting exposes the vulnerabilities of the SPAC model, particularly the reliance on the SPAC's continued listing status [4] - The case of Xiaoyu Tidata illustrates that even with stable business operations, a SPAC's delisting can abruptly halt the entire listing process [4] Group 2: Regulatory Changes and Challenges - New Nasdaq regulations effective January 17, 2026, will raise the minimum public float market value requirement from $5 million to $15 million and mandate that SPAC mergers must raise at least $25 million in public funds [4] - These regulatory changes create significant barriers for many small and medium-sized enterprises [4] Group 3: Advantages of the OTC Market - The OTC market offers a crucial buffer, allowing SPACs to continue merger transactions even after delisting from the main board [5] - OTC has lower financial requirements, with no strict profitability criteria and minimal annual fees ranging from a few thousand to $20,000 [6] - The listing process on the OTC market can be completed in 3-6 months, significantly faster than the 12-24 months required for a Nasdaq IPO [7] Group 4: Structured Compliance and Growth Opportunities - The OTC market features a four-tier compliance structure, catering to different stages of company development [8] - Companies already listed on domestic boards can issue ADRs on OTCQX without meeting stringent SEC registration requirements, facilitating exposure to U.S. investors [9] - The OTC market serves as a "golden stepping stone" for companies aiming to transition to Nasdaq or NYSE, with approximately 15% of Nasdaq-listed companies having previously grown on the OTC market [10] Group 5: Diverse Financing Options - The OTC market supports various financing methods, including private placements and convertible bonds, which are particularly suitable for light-asset companies in technology and biomedicine [11] - Companies can leverage the OTC market to access global financing while providing liquidity options for early investors [11] - The current delisting trend reinforces the need for Chinese companies to consider paths beyond the main board for U.S. listings [11]

Group 1 - The China Securities Regulatory Commission (CSRC) has published supplementary material requirements for five companies, including Guizhi Yan Pharmaceutical, which is undergoing a transition from private to public listing [1] - Guizhi Yan Pharmaceutical is required to clarify the compliance of its equity control structure and provide detailed information regarding share price changes in the 12 months prior to its application [1][2] - The company is also asked to explain the reasons why its beneficial owner, Shi Mingfeng, has not been recognized as a co-actual controller [1] Group 2 - Maius Pharmaceutical Technology, established in 2015 and headquartered in Shanghai, focuses on the research and development of innovative formulations and targeted small molecule drugs, particularly in oncology, immune system diseases, and anti-infection [3] - The company has developed a comprehensive R&D platform that integrates chemical drug screening and delivery, significantly enhancing drug development efficiency and precision [3] - Maius is set to achieve its strategic goal of going public on NASDAQ through a merger with DT Cloud Acquisition Corporation, with an overall valuation of $250 million [2]